Screener
ICU Medical ICUI SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by ICU Medical in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: ICU Medical’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:34 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000883984-26-000041
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| COST OF GOODS SOLD | 316,630 | 340,802 | 640,629 | 735,395 |
| GROSS PROFIT | 235,053 | 208,064 | 441,279 | 418,173 |
| OPERATING EXPENSES: | ||||
| Selling, general and administrative | 151,922 | 159,392 | 306,488 | 316,625 |
| Research and development | 22,702 | 21,867 | 43,982 | 45,158 |
| Restructuring, strategic transaction and integration | 21,302 | 16,218 | 38,103 | 32,915 |
| TOTAL OPERATING EXPENSES | 195,926 | 197,477 | 388,573 | 394,698 |
| INCOME FROM OPERATIONS | 39,127 | 10,587 | 52,706 | 23,475 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is ICU Medical's SG&A?
- ICU Medical (ICUI) reported SG&A of $151.92M in Q2 2026.
- How has ICU Medical's SG&A changed year-over-year?
- ICU Medical's SG&A decreased by 4.7% year-over-year, from $159.39M to $151.92M.
- What is the long-term trend for ICU Medical's SG&A?
- Over 4 years (2021 to 2025), ICU Medical's SG&A has grown at a 19.9% compound annual growth rate (CAGR), from $302.58M to $625.21M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about ICU Medical's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude